Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A

NCT02210091 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT02210091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02210091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2014
Completion date
October 23, 2015
Enrollment
75 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a